Investors are Taking Big Benefits From Dynavax Technologies Corporation (NASDAQ:DVAX) Stock’s Volatility
Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) tumbled -7.846% in morning trade Thursday. The stock extended its losses in after-hours. The stock shed -1.86% to $15.55.
On August 08, a clinical-stage immunotherapy company declared its intention to offer and sell $125.0M of shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also anticipates granting the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock to cover over-allotments, if any. Dynavax anticipates using the net proceeds from the projected offering to fund activities associated with preparing for the anticipated U.S. commercial launch of HEPLISAV-B, should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support continuing the clinical development of its lead investigational cancer immunotherapeutic product candidates, SD-101 and DV281, continuing research and development activities, and for other general corporate purposes, counting working capital.
Cowen, RBC Capital Markets and William Blair are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. is acting as lead manager for the offering.
The stock attained the volume of 10296100 shares contrast to its average daily volume of 2.74M shares. Trading volume is an important technical indicator a shareholder uses to confirm a trend or trend reversal. It is generally higher when the price of a security is changing, as the strength of any given price movement is measured mainly by the volume and shifts in trade volume can make observed price movements more significant. News about a company’s financial status, products, or plans, whether positive or negative, will typically result in a temporary increase in the trade volume of its stock. Higher volume for a stock is also an indicator of higher liquidity in the market. For institutional shareholders who wish to sell a large number of shares of a certain stock, lower liquidity will force them to sell the stock slowly over a longer period of time, to avoid losses because of slippage. The stock, as of recent close, has shown weekly downbeat performance of -6.758% which was maintained at 72.28% in 1-month period, and is up 301.26% in this year. The company now has a market value of $891.40M.
The stock, after recent close, is 58.03% above their SMA 50 and 26.17% from SMA20 and is 139.06% above than SMA200. 61.27% shares of the company were owned by institutional investors. The company has 115.77 value in price to sale ratio while price to book ratio was recorded as 5.596. It beta stands at 1.56.
The average 12 month target price among brokers that have covered the stock in the last year is $24.32. Analyst mean recommendation for this stock stands at 1.8. Analyst recommendations as stated on FINVIZ are rated on a 1 to 5 scale. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. The consensus recommendation is the average rating on a stock by the analyst community.
